Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment

J Blade, Pieter Sonneveld, JES Miguel, HJ Sutherland, R Hajek, A Nagler, A Spencer, T Robak, MT Cibeira, SH Zhuang, JL Harousseau, RZ Orlowski

Research output: Contribution to journalArticleAcademic

58 Citations (Scopus)


A retrospective analysis was undertaken of patients (n = 193) with renal insufficiency (creatinine clearance [CrCl] < 60 mL/min) from a phase III trial comparing bortezomib +/- pegylated liposomal doxorubicin (PLD) in relapsed/refractory myeloma (n = 646). The response rate (49% vs. 42%) and median time to disease progression (331 days vs. 199 days) were comparable or slightly better for patients with renal insufficiency treated with PLD/bortezomib compared with patients treated with bortezomib alone. There was a steady, clinically meaningful improvement in renal function for patients with renal insufficiency in both treatment arms. However, patients with impaired renal function were at a slightly increased risk of a drug-related serious adverse event (28% vs. 19% for CrCl < 60 and ! 60 mL/min, respectively).
Original languageUndefined/Unknown
Pages (from-to)352-355
Number of pages4
JournalClinical Lymphoma & Myeloma
Issue number6
Publication statusPublished - 2008

Research programs

  • EMC MM-02-41-03

Cite this